Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
Bioorg Med Chem Lett
; 16(4): 960-3, 2006 Feb 15.
Article
em En
| MEDLINE
| ID: mdl-16297626
ABSTRACT
A Hit-to-Lead optimisation programme was carried out on a high throughput screening hit, the thiazolopyrimidine 1, resulting in the discovery of the potent, orally bioavailable CXCR2 antagonist 29.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Pirimidinas
/
Tiazóis
/
Receptores de Interleucina-8B
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article